When the F.D.A. approved the drug Aduhelm, the first Alzheimer’s treatment to receive the agency’s endorsement in almost two decades, it gave hope to many.
But the decision was contentious; some experts say there’s not enough evidence that the treatment can address cognitive symptoms.
What is the story behind this new drug?
Guest: Pam Belluck, a health and ... Show More
Sep 22
Trump Banned the Media. This Time, the Media Struck Back.
For every day of Donald J. Trump’s presidency, there has been a camera from a major television network pointed at him. But on Monday, that all changed.Zolan Kanno-Youngs and Michael M. Grynbaum discuss the face-off between the president and the press. Guest:Zolan Kanno-Youngs, a ... Show More
27m 39s
Sep 21
The Trump Administration Defangs the Endangered Species Act
In its second term, the Trump administration has increased its efforts to undo environmental regulations. Last week, it became clear that the Endangered Species Act, one of America’s bedrock environmental laws, would be losing some of its most important protections.Catrin Einhorn ... Show More
24m 13s
Mar 2023
How Well Does A New Alzheimer's Drug Work For Those Most At Risk?
A new drug for Alzheimer's disease, called lecanemab, got a lot of attention earlier this year for getting fast-tracked approval based on a clinical trial that included nearly 1,800 people. It was the most diverse trial for an Alzheimer's treatment to date, but still not enough t ... Show More
13m 46s
Nov 2021
Why Aduhelm, a new Alzheimer's treatment, isn't reaching many patients
Aduhelm, known generically as aducanumab, is the first drug to actually affect the underlying disease process associated with Alzheimer's. Yet sales have been limited, and the drug is reaching very few patients — at least so far. It's expensive, risky and likely doing little to i ... Show More
9m 45s
Apr 2023
Audio long read: Conquering Alzheimer’s — a look at the therapies of the future
Last year, researchers announced that the Alzheimer’s drug lecanemab lowered the amount of amyloid protein plaques associated with the disease in the brains of participants in a clinical trial, and slowed their cognitive decline.Now, researchers are looking to drug combinations, ... Show More
17m 31s